CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study

Data ReadoutpositiveNexviazymePositive
AI Analysis

Summary

Sanofi's Nexviazyme met its study goals in infantile-onset Pompe disease, demonstrating positive clinical trial results for the enzyme replacement therapy.

Clinical Trial Data

Primary Endpoint

Met

Importance:6/10
Sentiment:
0.70
clinical_trialenzyme_replacement_therapyrare_diseasepompe_disease
Related Companies

Read the original article

Published by yahoo_finance on July 1, 2026 1:22 PM

Read Original